IP Library Granted Patent US 9,012,517
Granted Patent B2
US 9,012,517 · App. 14/219,652 · Granted Apr 21, 2015

Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation

Inventors: Karina Heredia Guillen (Santa Barbara, CA); Ahmet Tezel (Fort Worth, TX)
Assignee: Allergan, Inc.
A61K47/36A61L27/20A61L27/52A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,517
App. No.
14/219,652
Granted
Apr 21, 2015
Kind
B2
Abstract

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Claims (28)

1. A method for making a hydrogel for soft tissue augmentation, the method comprising:

providing at least one cross-linkable biocompatible polymer;

dissolving said at least one cross-linkable biocompatible polymer in a buffered solution, wherein said buffered solution maintains a pH from approximately 6.0 to approximately 8.0;

adding at least one zero-length cross-linking agent to said buffered solution to form a reaction mixture; and

allowing said reaction mixture to stand for a time appropriate to form the hydrogel suitable for soft tissue augmentation, wherein said hydrogel comprises a cross-linked biocompatible polymer having zero-length cross-linked moieties;

wherein at least one said cross-linkable biocompatible polymer is hyaluronic acid; and

wherein said zero-length cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

2. The method according to claim 1 further wherein said buffered solution is phosphate buffered saline having a pH of between 6.5 and 7.5.

3. The method according to claim 1 further including N-hydroxysuccinimide (NHS) in said adding step.

4. The method according to claim 1 further comprising a dialyzing step after said allowing step.

5. The method according to claim 1 further comprising at least one second cross-linkable biocompatible polymer.

6. The method according to claim 5 wherein said at least one second cross-linkable biocompatible polymer is a protein.

7. The method according to claim 6 wherein said at least one second cross-linkable protein is elastin.

8. The method according to claim 1 further comprising adding an active agent selected from the group consisting of enzyme inhibitors, anesthetic agents, medicinal neurotoxins, antioxidants, anti-infective agents, anti-inflammatory agents, ultraviolet (UV) light blocking agents, dyes, hormones, immunosuppressants, and combinations thereof.

9. A method of making a hydrogel for soft tissue augmentation, the method comprising:

reacting at least one cross-linkable biocompatible polymer with at least one zero-length cross-linking agent at neutral pH, thereby forming a cross-linked biocompatible polymer comprising zero-length cross-linked moieties;

wherein at least one said cross-linkable biocompatible polymer is hyaluronic acid (HA); and

wherein the zero-length cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

10. The method according to claim 9 , wherein the zero-length crosslinking agent is reacted with the at least one cross-linkable biocompatible polymer in the presence of N-hydroxysuccinimide (NHS).

11. The method according to claim 9 , wherein the neutral pH is between about 6.0 and about 8.0.

12. The method according to claim 9 , wherein the neutral pH is between about 6.5 and about 7.5.

13. The method according to claim 9 , wherein the neutral pH is about 7.0.

14. The method according to claim 9 , wherein the neutral pH is maintained by a phosphate buffered saline solution.

15. The method according to claim 9 , further comprising at least one second cross-linkable biocompatible polymer.

16. The method according to claim 15 , wherein the at least one second cross-linkable biocompatible polymer is a protein.

17. The method according to claim 16 , wherein the at least one second cross-linkable protein is elastin.

18. The method according to claim 9 , further comprising adding an active agent selected from the group consisting of enzyme inhibitors, anesthetic agents, medicinal neurotoxins, antioxidants, anti-infective agents, anti-inflammatory agents, ultraviolet (UV) light blocking agents, dyes, hormones, immunosuppressants, and combinations thereof.

19. The method according to claim 18 , wherein the active agent is an anesthetic agent, which is lidocaine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: GUILLEN, KARINA HEREDIA; TEZEL, AHMET
To: ALLERGAN, INC.
Reel/Frame 035195/0091 →
Continuity (3)
Division 13052690 · Mar 21, 2011
Provisional Application 61316283 · Mar 22, 2010
Related Publication 20140206774A1 · Jul 24, 2014